• GANT61 and GLI2–Ferroptosis Research Context

  2026-10-07

  GANT61 is a research tool used to examine GLI transcription-factor activity within Hedgehog signaling. Recent bladder-cancer findings connect GLI2 to PRDX1-mediated ferroptosis resistance and cisplatin response, but the available evidence remains preclinical. This overview separates supplier descriptions from published findings and defines the limits of applying GLI inhibition across cancer models.

• CA-074 Me, Cathepsin B and Necroptosis Research

  2026-10-07

  A source-grounded overview of CA-074 Me as a research tool for studying cathepsin B, lysosomal membrane permeabilization, necroptosis and inflammation, with emphasis on published findings, evidence strength, selectivity limits and applicability boundaries.

• Camptothecin and Adaptive Genome Stability

  2026-10-06

  Camptothecin is a topoisomerase I inhibitor widely used to study DNA damage, apoptosis, autophagy, and cellular senescence. This article develops a distinct interpretive framework linking its acute DNA-damage response to, but carefully separating it from, the heritable mutagenesis switches described in a 2026 Cell study.

• Cathepsin B and L Activities in Barley Senescence

  2026-10-06

  Schepetkin and Fischer combined substrate profiling, inhibitor sensitivity, activity-probe labeling, and immunoblotting to show that cathepsin B- and L-like protease activities rise during developmental senescence in barley leaves. The study links this proteolytic shift with Rubisco and total-protein loss while also showing why inhibitor data alone cannot assign activity to one plant protease.

• Z-DEVD-FMK: Caspase-3 Inhibition in Context

  2026-10-05

  Z-DEVD-FMK is commonly used as a pharmacological probe of caspase-dependent apoptosis, but its reported activity extends beyond caspase-3. This overview examines the compound’s research context, findings from a melanoma-cell preprint, proposed applications in apoptosis assays and neuroprotection research, and the limitations that prevent selective or clinical interpretation.

• Gastrin I (Human): Mechanism and GI Models

  2026-10-05

  Gastrin I is an endogenous peptide hormone that signals through CCK2 receptors to regulate gastric acid secretion. This article distinguishes supplier-reported product attributes from peer-reviewed evidence and explains why hiPSC-derived intestinal organoids support pharmacokinetic research but do not independently validate gastric acid assays.

• (R)-MG132 in Cancer Metabolism Research

  2026-10-04

  A source-grounded overview of (R)-MG132 as a stereoisomeric proteasome control, its relevance to ubiquitin-proteasome system research, and how it may help frame mechanistic interpretation of a 2026 Advanced Science study on HNRNPU K181 lactylation and serine metabolism in cervical cancer.

• CA-074 and Cathepsin B in Necroptosis Research

  2026-10-03

  A source-grounded overview of CA-074, cathepsin B biology, and the evidence linking lysosomal membrane permeabilization to necroptosis, with emphasis on interpretation, applications, and limitations.

• (S)-Mephenytoin for CYP2C19 Pharmacokinetic Studies

  2026-10-02

  Use (S)-Mephenytoin as a defined CYP2C19 substrate to connect enzyme kinetics with human intestinal organoid models. Its measurable 4-hydroxylation pathway supports assay qualification, model comparison, and troubleshooting in translational pharmacokinetic studies.

• Ferroelectric Artificial Photoreceptor for Visual Adaptation

  2026-10-01

  This study introduces a ferroelectric–liquid metal hybrid film that combines azo polymer-grafted liquid metal nanoparticles with a P(VDF-TrFE) matrix to reproduce both low-light and bright-light visual adaptation. In retinal-degeneration models, the implant generated strong visible-to-near-infrared photoelectric responses and improved light sensitivity, while electrophysiological, behavioral, and three-month biocompatibility results support its potential as a broadly responsive retinal prosthesis platform.

• SGC-CBP30: A Causal Assay for LUAD

  2026-10-01

  SGC-CBP30 is a selective CREBBP/EP300 bromodomain inhibitor for dissecting enhancer-dependent transcription in lung adenocarcinoma. This article develops a causal assay framework that connects super-enhancer activity, TGF-β/SMAD3 signaling, and measurable transcriptional outcomes.

• DiscoveryProbe FDA-approved Drug Library for AML

  2026-09-30

  Explore how the DiscoveryProbe FDA-approved Drug Library can support mechanism-first AML research, using the mebendazole–TUBA1A–ZBP1 PANoptosis study to design stronger drug repositioning screening and target-validation workflows.

• DiD for Inflammatory Cell Tracking

  2026-09-30

  DiD (DiDC 18 (5)) provides a red membrane-labeling strategy for resolving macrophage migration, adhesion, and cell-cell interactions in inflammatory models. This article connects probe behavior with the mitochondrial ROS-loop biology of diabetic periodontitis while defining assay boundaries and practical controls.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-09-29

  Song and colleagues show that murine norovirus uses the host membrane-rupture factor NINJ1 to release the viral immune-modulatory protein NS1. Combining CRISPR screening, cell biology, mutagenesis, and mouse infection models, the study identifies a caspase-3–NINJ1 pathway that is mechanistically selective but occurs alongside broader damage-associated molecular pattern release.

• Y-27632 Dihydrochloride ROCK Inhibitor Workflows

  2026-09-29

  Y-27632 dihydrochloride gives researchers a practical way to perturb ROCK-dependent cytoskeletal remodeling, cell survival, organoid recovery, and invasion phenotypes. This workflow-focused guide also shows how lessons from a CFTR electrophysiology study can improve timing controls and endpoint selection without confusing ROCK inhibition with CFTR modulation.

8054 records 1/537 page Next 12345 下5页 Last page